alexa VAC-3S Vaccine, A Novel Approach To The Therapeutic Management Of HIV Infection. Overview Of Phase I And Phase II Clinical Vaccine Development Programs
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Raphael Ho Tsong Fang, O Launay, C Katlama, J Crouzet, B Autran, V Vieillard, P Debre and S Gharakhanian
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.020
Abstract
Background: HIV infection is a chronic persistent inflammatory disease. Morbidity remains despite antiretroviral therapy (ART) Achieving functional cure is now a goal. VAC-3S vaccine is comprised of 3S peptide, a highly conserved gp41 motif, commercially used carrier and adjuvant. In cohort or primate studies, anti-3SAb correlate with lack of CD4 decrease, affect on immune/inflammatory biomarkers, HIV reservoirs. Phase I: FTIH randomized, double-blind, placebo-controlled assessment of safety of 0.1, 1, 10, 20 μ g, IM, q4wks in ART controlled patients (pts) & a booster in 1 & 10 μ g groups. 33 HIV pts (29 M) were included. Age 47 yrs (32-54), none had detectable HIV RNA, CD4 710 c/mm3 (311-1187). No viral rebound under treatment. 1 SAE, non-related. Gr1-2 AEs: local reactions, fever, LFT increases (3) myalgia(1). Six pts in 1 to 20 μ g doses increased anti-3SAb above the target 50 Units. Ab titers subsequently decrease but can be effectively re-boosted (n=3/6 pts). Phase II: Assessment of therapeutic properties of VAC-3S, at 16, 32 & 64 μ g doses, combined with standard ART. This European multicenter, randomized, double blind, placebo-controlled study will assess immunogenicity and efficacy on HIV reservoir, inflammatory biomarkers, a full immunological panel in pts on ART with CD4 count 200-500 c/mm3. Statistical methodology will allow extensive subgroup analysis. Conclusion: VAC-3S HIV therapeutic vaccine is immunogenic, it is safe at the 4 doses studied. In phase IIA, dose escalation continues. Phase IIB will notably assess VAC-3S in combinations that can potentially lead to full immune restoration and contribute to a functional cure of HIV
Biography
Raphael Ho Tsong Fang possesses 15 years of experience in HIV field, immunology and pathophysiology. He is currently Associate Medical Chief Officer at InnaVirVax, a European clinical stage biotechnology developing cutting edge immune-based treatments for infectious and major chronic diseases. He actively participates into the development of therapeutic vaccines against the disease induced by HIV, from R&D to non-clinical and clinical development. He is a Doctor in Veterinary Medicine from the Medicine University of Nantes and holds a PhD in Medical Virology from Denis-Diderot University of Paris. He completed his Post- doctoral studies at the Department of Microbiology, Immunology and Molecular Genetics at UCLA
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version